Myriad Genetics, Inc.
MYGN
Market Cap$696.82M
Close$
$-8.81
318.7% downside
Current Fair Value
318.7% downsideOvervalued by 318.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $696.82 Million |
|---|---|
| Enterprise Value | $744.22 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.18 |
| Beta | 1.88 |
| Outstanding Shares | 90,900,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.92 |
|---|---|
| PEG | 9.26 |
| Price to Sales | 0.45 |
| Price to Book Ratio | 0.5 |
| Enterprise Value to Revenue | 0.9 |
| Enterprise Value to EBIT | -6.71 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...